Terms ending in 2033
Every in-force patent on Acceleron Pharma Inc.'s record whose computed term ends in 2033, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 9,809,636 | Methods for Increasing Red Blood Cell Levels Comprising Administering BMP9 In force · High confidence | Suragani, Rajasekhar Naga Venkata Sai | In force | High confidence | |
| US 10,344,066 | Methods and Compositions for Increasing Red Blood Cells In force · High confidence | Suragani, Rajasekhar Naga Venkata Sai | In force | High confidence | |
| US 10,829,534 | Methods and Compositions for Increasing Red Blood Cells In force · Medium confidence | Suragani, Rajasekhar Naga Venkata Sai | In force | Medium confidence | |
| US 11,807,673 | Methods and Compositions for Increasing Red Blood Cells In force · Medium confidence | Suragani, Rajasekhar Naga Venkata Sai | In force | Medium confidence | |
| US 8,058,229 | A Method of Increasing Red Blood Cell Levels or Treating Anemia in a Patient In force · High confidence | Acceleron Pharma Inc. | In force | High confidence |
5 of 5 patents shown. Soonest term end first, then patent number.
1 of these is in force and held by Acceleron Pharma Inc..
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.